ARC Finance is a non-banking financial company that provides personal and corporate loans, trades in equity securities, and distributes third-party financial products.
The company operates in a highly commoditized lending and trading space with no evidence of low-cost funding or proprietary distribution. Financial metrics contradict any moat claim, as average ROCE and ROE are near zero, indicating a lack of competitive advantage.
Management has prioritized equity dilution through a large rights issue to fund a balance sheet primarily composed of loans and stock-in-trade. Returns on this capital are negligible, with net margins and ROE failing to exceed basic inflation or cost of capital.
The company's collapse was driven by the inevitable crystallization of credit risk from its opaque loan book. By funneling capital raised through equity dilution into unsecured loans to private entities, management essentially operated a wealth-transfer mechanism rather than a productive enterprise. As these private borrowers defaulted, the already razor-thin returns on equity vanished, and the negative cash conversion cycle finally starved the firm of liquidity. The market eventually realized that the 'assets' on the balance sheet were largely unrecoverable, leading to a permanent impairment of capital as the stock price converged with its negligible intrinsic value.
RichFakir rates ARC Finance Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, ARC Finance Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on ARC Finance Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of ARC Finance Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →